Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There will need to be some impetus for buyers to come into the ticker. The reason this R/S happen so soon after the last one was because of the buying frenzy that took place with hype around the virus. Obviously, the PPS can drift lower with no news and low volume like it has for awhile but that benefits no one even Sabby who has the opportunity to make some serious cash with the raise in share price. NSPX has done nothing to help the cause and it is certainly possible for a business (or lack of) as usual. A stash of 145 million shares is not so good if no one has a reason to buy them.
Covid-19 hype is played out..Ridgeway has not materialized as yet..mipsagargin is on hold.. No word from MediciNova.. no 1st quarter filings .. still no word from the company.. R/S is official..who would buy the 145mil shares hanging out there. What is the hype machine going to do to get some volume? Lots of shares to be bought!
I don't think it has traded yet so technically it should be .09. .003 (yesterdays close) x 30.
Why not the 1:500 and rinse all ultra clean?
If Sabby indeed controls the company and therefore the stock this would be an advantages time for a run up for the PPS. They would have shares to convert at low prices and sell as price escalates. Hard to think that sabby is involved for watching this ticker fade to nothing!
Will they need to file the 10Q under NSPXD if not when will they be required to file the 1st quarter 10Q?
For sure a real puzzle! You would think that eventually something positive would come from this ticker. The waiting game can frustrate even the strongest of believers. The choice has been made so ride it to where it is going. The risk has been taken just waiting on the reward if or when it materializes!
Update on Phyton.. European Patent Office certified patent for production of thapsigargin on 5/18/20. Us patent office has hearing on US patent for the same production of thapsigargin on July 16. Seems the commercial production of thapsigarin (active ingredient in mipsagargin) is moving forward. Soon thapsigargin will be available in robust quantities for an active PH III mipsagargin trial.
Quiet this AM.. heating up a little in PM..nice 600K slap @ 42
Been relatively quiet lately but buyers came out in force today.. they were hungry most of the day. The ticker remains resilient.. the ever ready bunny of otc bio. This stock has been in the game awhile and maybe its time is about to arrive. One day does not make any trend so we will see if some follow thru action is on the horizon. Filings due 6/29.. maybe some thing positive? anyway up 46% on 20 million shares with a RS cloud hanging over the ticker should generate a spark of wonder.
Please not the virus hype..been there done that. Maybe or not we beat that horse to death!
President and CEO of Ridgeway Therapeutics... working with Inspyr for the greater good!
DR. COLIN HISLOP, M.B.B.S.
SENIOR VICE PRESIDENT, CLINICAL & DEVELOPMENT OPERATIONS
Dr. Hislop has over 30 years of experience in drug development including small molecules, peptides and biologics, across therapeutic areas in both large pharma and start-up companies. Prior to joining Eiger full-time, Dr. Hislop was the Company’s senior medical advisor to the Progeria program and was instrumental to Eiger’s first NDA submission of Lonafarnib for the treatment of Progeria and Progeroid Laminopathies. Prior to joining Eiger, Dr. Hislop served as Chief Medical Officer at Versartis and Anthera. He was previously Vice President and Head of Clinical Development at Peninsula Pharmaceuticals developing doripenem for systemic infections. Peninsula was acquired by J&J for $245 million. Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics where he developed and filed an NDA for Ranexa® for angina. CV Therapeutics was acquired by Gilead for $1.4 billion. He previously led the development of Actonel® through initial FDA approvals for osteoporosis at Proctor & Gamble. Dr. Hislop began his industry career at Eli Lilly as Medical Director of Endocrinology for insulin and growth hormone. During his career, Dr. Hislop has been involved in all phases of drug development from IND to Phase 4,and has led numerous US, European and global regulatory filings, including 4 NDAs.
Dr. Hislop earned a Bachelor of Science in Medical Biochemistry from the University of Surrey and a Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.) at the University of London.
Loaded up a while back so not buying but holding and waiting this ticker out. Never have seen any negative info on mipsagargin always a prodrug with potential in many solid tumor applications. The only down side has not been concerning mipsagargin but the formulation of thapsigargin (main ingredient) as noted that it is difficult to make in commercial quantities and the current process to make it is expensive. Phyton is in the process of solving that riddle.
What "they say" is not always correct.. follow your own lead at least you will then be able to pat yourself on the back or know who to blame when this trade comes to conclusion. Good or bad it will come to a conclusion.
Could be he/she is in the know and wants in!
1,000,000 shares @ .0031
I'll let others rain on your thoughts..I won't. Although highly unlikely that a sale has happened.. it may be possible that behind the scenes other
negotiations are taking place for positive developments similar to the licensing with Ridgeway and association with MedicNova. More evidence coming out all the time regarding thapisgargin and the cancer killing prowess of the plant.
Although Dr. Hislop is listed as President and CEO of Ridgeway his day job is also listed as Sr. V.P. at Eiger Bio Pharmaceuticals. You may want to try reaching out to him there. Dr. Hislop has a noted history of important staff positions at various Bios and now it seems with Ridgeway he is stepping out as the boss. A success from his association with Inspyr would be a major move for his resume!
I agree.. I'm fairly certain that anyone who would buy this ticker with a potential RS ahead would be a risk taker. However, between tomorrow and when/if the RS actually is issued something may develop. Past performance does not bode to that happening but nothing is out of the realm of possibilities. Crazy happenings seem to be the norm these days.
Mostly on the ask.. looking for the exit! Had enough and patience has run out! Good time to throw some cash at these super cheap prices just incase something pops. Not much risk way down here!
You are correct..presently the IP hasn't shown much interest and may never. All my shares are like call options not much invested and potential if something comes up. No call options on the OTC but if you buy low enough you can sit back and have no concern about the chump change that is invested. Strange things happen all the time.. who would think the S&P futures going limit down multiple times.. traded commodity futures for many years and haven't seen it too often.
You have to think of what is the purpose of NSPX. My business had a lot of moving parts but was basically simple and had a purpose. I also own shares in NSPX. It is hard to think that after 17 years and 60+ million spent and all the IP, patents and research taken place that the purpose of this ticker is to be an avenue to take advantage of naive investors. I realize that as a clinical stage pre-revenue bio it will have its share of challenges.. regardless nothing scares me about this investment and will also hold to see what happens.
Daily fluctuations or trends either up or down actually mean little to the overall outcome of this ticker. It has basically traded in the same region (except for the covid-19 hype) all year. Look at the chart from Jan and Feb an that is what we are getting now. It is more like a private company than a public one. There are only 133 record stock owners of which Sabby owns a large portion of the shares. Sabby controls the stock because they loaned NSPX money to stay alive. The loans (debentures) are written in Sabbys favor (he who has the gold makes the rules). However, in the process of staying alive NSPX has the opportunity to prove to all that the IP and patents they own are worthy. If they can't prove that most will lose their investment (rightfully so when you invest in a worthless stock). However, if on the other hand value comes somehow and from somewhere the investment will prove worthy.
Between January 1, 2020 and March 31, 2020, the Company issued an aggregate of 131,351,247 shares of common stock upon the conversion of $451,662 principal amount of debentures. From 2019 10-K.
The RS will NOT generate millions of dollars.
You are so correct that anything is possible with this ticker. Surprised that so far it has not tested the low and that volume is fairly robust even with the RS hanging over the stock. A double bottom may be forming and with the moving off oversold it may be an interesting week.
You would assume there is some sort of agreement between NSPX and Medicinova. I doubt very seriously that there is upfront monies to include mipsagargin in the patent however if this association leads to a NDA (new drug application) that would be a different event.
The 1st quarter 2020 10-Q is due 6/29. After that a bunch of debentures mature on July 16 and of course there is the pending (if and when it happens) RS. Also, there is continuing speculation concerning Ridgeway Therapeutics and now MediciNova, Phyton Pharmaceuticals and maybe others that may have an effect on NSPX going forward. I would not count this ticker dead just yet and holding at these prices may be sound judgement!
Between January 1, 2020 and March 31, 2020, the Company issued an aggregate of 131,351,247 shares of common stock upon the conversion of $451,662 principal amount of debentures. Note from 10-K.That averages to .0034/share. So who would you think was selling stock during the covid-19 hype? So who would you think wants the stock low to get more shares in conversion? Who would you think has a lockdown of any communication from the company and installed a puppet for ceo? It would not be surprising that prior or after the RS some event may elevate the PPS so converted shares can be unloaded at higher margins.
Mipsagargin also showed some efficacy with Gliobastoma (brain cancer) so that is certainly why MedicNova list mipsagargin on their revised patent application for the study of brain cancer. Combination drug therapy is becoming more prevalent than stand alone drugs to treat various cancers. Maybe something will come from this association. Ridgeway partner has done nothing and may end without nothing being accomplished. Dr. Hislop is a smart guy, well respected, so something still may come of that partnership. Other may also pop up as time goes on!
G-202 (mipsagargin) was originally developed at John Hopkins as a prostate cancer drug. Pre-clinical trials with communication with the FDA changed the designation to solid tumors therapy. It wasn't until the PH I dose escalating trial with patients with various solid tumors that the efficacy was noted with patients with liver cancer. So what started as one therapy drug expanded thru trials to have the possibility in many solid tumors. Obviously, that proficiency has not yet developed and may not in the future but the speculation is that it will.
I walked that line many times in the past. It's a fine line between absolute genius if it works out the opposite (you name it) if it doesn't.
Private funds Sabby Healthcare master and Sabby Volitude warrant master each hold 16.6 million shares of NSPX. Minnimum investment if you want to get in the funds are $500,000 and $300,000 respectively. Combined the funds have a GAV (gross asset value ) of $198 million. They are limited funds 28 investors in one more in the other. Hard to justify why sabby would be interested in sub penny OTC that is currently trading for .0042 a share.
Did that last oct... stock price tanked volume slowed little money was generated to pay off anything. You would think Sabby would be more interested in helping NSPX some how some way increase the existing share price so they could cash in on the 33+ million cheap shares they own forget about the RS and the debt.
Others keep posting that Sabby is going to make all the money but never explain how at these prices. They also state all the patents, IP, research and collaboration with others are worthless. So if everything is without value why would sabby continue to pour cash into this company. Anyone can justify NSPX as a real loser by it's past performance but the ticker has been resilient.. the story may not be over quite yet.
It appears in the pre 14C that sabby (2 funds) own 33.3 Million shares of common stock.. that's also the figure in the 10-K. At today's price that's 149K. On the most recent 10-k balance sheet the debenture liability is 2.6 million. So they are owed 2.6 million and have stock that's worth 149K .. study those numbers hard and ask yourself how they are going to walk away with all the money.
I respect all that input and post on this board! All have the rite to their opinion. Flafylersfan has posted many right on info concerning this stock.. now one is doubting his experience in pennies. However, his crystal ball is just as cloudy as mine or yours as to what is going to come of this ticker and the IP it owns (all the material has been posted). As for the current RS.. Sabby or NSPX had nothing to do with eating up all the AS. As of DEC 19 there were only 11.4 million shares outstanding. It was the covid-19 hype perpetrated by many on this board that got investors getting in on the "stock of the century". Without that there would be no current RS. We are back to pre hype days..nothing has changed.
I won't argue that Sabby is inflicting toxic debt on NSPX and may get their pond of flesh from shareholders. However, when or if a deal comes forth that provides an influx of cash to NSPX things may change rapidly. What Sabby is owed 2.8 million is peanuts for what is possible in bio.
Ha! Most of "huge" debt you talk of is either accrued or deferred. Sabby will extend mature dates on the debentures and all will go as usual. The hype was the cause of third RS nothing that the company was part of. The company will "operate" as noted in the filings seeking licensing, partnering etc. while other research organizations study the large amount of IP that is owned by NSPX. Read the filings, make the right decision. Patience never said it would be easy!
Good question.. I would know if I had a chance to audit their books. But I would surmise a big chunk was the to catch up on the late filings (2 10k and 6 10Q) that were late and to pay off FLG Partners. However, your insinuation that some insiders are siphoning off money is more than possible!
Of the 1.8 million of accrued expenses on the balance sheet are 1.4 miliion for compensation and benefits owed to past employees and most likely board members. The money may be owed but there has been now mention of legal action from them to file suits for the money. That figure has remained constant from the 2018 10-k. Although the money is owed it is a stretch to categorize them as "must be paid" in the current sense of NSPX's financial woes.